Evaluation of IGF1/IGFBP3 Molar Ratio as an Effective Tool for Assessing the Safety of GH Therapy in Small-for-Gestational-Age, GH-Deficient and Prader-Willi Children

Conclusions: We consider IGF1/IGFBP3 molar ratio to be a useful additional parameter for assessing therapeutic safety on rGH, keeping values within the normal range for age and pubertal stage. PMID: 30759961 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30759961?dopt=Abstract

Source: JCRPE Journal of Clinical Research in Pediatric Endocrinology - February 16, 2019 Category: Endocrinology Tags: J Clin Res Pediatr Endocrinol Source Type: research